Woldanorf,
Yes they can negotiate the value - BUT they don't yet have PRV...they can apply for it when they submit their marketing application after P2B.
At the moment they have RPDD status for ATL1102, which is a prerequisite to apply for PRV.
So, it won't help them now with funding, but RPDD status is useful / valuable for any Big Pharma wanting equity / TO play.
.
ATL1102 US Patent - very interesting, page-41
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.9¢ |
Change
-0.046(34.1%) |
Mkt cap ! $80.23M | |||
| Open | High | Low | Value | Volume |
| 8.7¢ | 9.0¢ | 8.6¢ | $2.082M | 23.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 250808 | 8.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.9¢ | 312804 | 3 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |